anti-4-[(5-羟基金刚烷-2-基)氨基]-1H-吡咯并[2,3-b]吡啶-5-甲酰胺氢溴酸盐
anti-4-((5-Hydroxyadamantan-2-yl)amino)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide hydrobromide
产品编号 :
ACDCTB061
Cas No. :
1353219-05-2
包装规格
纯度
目录价
会员专享价
库存
数量
抱歉,暂无牌价信息
晶智化学产品均仅供科研使用。在任何情况下,我们均不提供用于动物或人体用途的产品或服务。
基础信息
CAS No.
1353219-05-2
中文名称
anti-4-[(5-羟基金刚烷-2-基)氨基]-1H-吡咯并[2,3-b]吡啶-5-甲酰胺氢溴酸盐
英文名称
anti-4-((5-Hydroxyadamantan-2-yl)amino)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide hydrobromide
别名
Peficitinib hydrobromide (JAN/USAN);Peficitinib hydrobromide;4-(5-Hydroxytricyclo3.3.1.13,7dec-2-yl)amino-1H-pyrrolo2,3-bpyridine-5-carboxamide hydrobromide (1:1) stereoisomer;Peficitinib Hydrobromid;anti-4-((5-Hydroxyadamantan-2-yl)amino)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide hydrobromide;RMA-849
标准英文名
4-((5-hydroxyadamantan-2-yl)amino)-1H-pyrrolo[2,3-b]pyridine-5-carboxamide hydrobromide
分子式
C1 8 H2 3 BrN4 O2
分子量
407.31
精确分子量
406.10
SMILES
Br.NC(=O)C1=C(NC2C3CC4CC2CC(O)(C4)C3)C2=C(N=C1)NC=C2
标准SMILES
Br.NC(=O)C1C=NC2NC=CC=2C=1NC1C2CC3CC(O)(CC1C3)C2
用途
Peficitinib hydrobromide is an orally active Janus kinase (JAK) inhibitor developed by Astellas Pharma for the treatment of rheumatoid arthritis (RA) in patients who have had an inadequate response to conventional therapies.
InChIKey
ZUVPMAPXNYGJQC-UHFFFAOYSA-N